Key facts
- It has raised $74.8M; the latest was IPO ($28.2M) in Mar 2026.
- Notable investors include Premier Partners, DAYLI Partners, Kolon Investment, Timefolio Asset Management, SJG Partners — 12 tracked in total.
- Status: Publicly Held.
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Kanaph Therapeutics (KRX: 0082N0)
- ·The full record, as it builds
Funding rounds
No funding rounds for Kanaph Therapeutics (KRX: 0082N0) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kanaph Therapeutics (KRX: 0082N0)
Kanaph Therapeutics Inc is a biotech company dedicated to developing anticancer drugs and ophthalmic disease treatments based on human genome-based drug development technology. Its core technology lies in identifying novel targets with high unmet medical needs through the analysis of human genome data and disease-specific biological signatures, and in developing drugs of various modalities, including bispecific antibodies, antibody-drug conjugates (ADCs), and synthetic drugs, based on these findings. The groups pipeline products are KNP-101, KNP-301, KNP-502, KNP-503, KNP-504, and KNP-701.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2019
- Employees
- 30
- Website
- kanaphtx.com/
- Ownership
- Publicly Held
Kanaph Therapeutics (KRX: 0082N0) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kanaph Therapeutics (KRX: 0082N0) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kanaph Therapeutics (KRX: 0082N0) in its N-PORT filings yet. We sweep new filings monthly.